NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Sinclair & Co.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Mayne Pharma Names Q. Dwight Lewis VP of Quality for U.S. Operations - With more than 25 years of pharmaceutical industry experience, Lewis brings to his role expertise in new chemical entity development, API and dosage form manufacturing, generic drug development and contract services
Mayne Pharma Names Q. Dwight Lewis VP of Quality for U.S. Operations

 

NewswireToday - /newswire/ - Greenville, NC, United States, 2014/10/21 - With more than 25 years of pharmaceutical industry experience, Lewis brings to his role expertise in new chemical entity development, API and dosage form manufacturing, generic drug development and contract services.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Mayne Pharma has appointed Q. Dwight Lewis as vice president of quality for its operations in the United States.

Lewis is responsible for managing all quality-related functions to ensure that Mayne Pharma’s U.S. pharmaceutical operations which range from laboratories to manufacturing lines continue to comply with global regulatory agency and industry standards.

“Drug product integrity doesn’t occur spontaneously; it is the result of thoughtfully considered and deliberately executed quality standards and operations,” said Stefan Cross, president of Mayne Pharma’s U.S. operations. “Dwight’s knowledge and expertise in quality compliance and assurance will support Mayne Pharma’s ability to deliver superior pharmaceutical services and products to our clients and the patients we collectively serve.”

Before joining Mayne Pharma, Lewis was senior director of quality for Teva Pharmaceuticals, where he managed quality assurance and control functions for solid dose manufacturing. Prior to that, he served as vice president of quality for Irix Pharmaceuticals, and as director of quality operations for DSM Pharmaceuticals.

Lewis brings to his new role expertise in new chemical entity (NCE) development, active pharmaceutical ingredient (API) and solid dose form manufacturing, generic product development, and contract services. He holds a bachelor’s degree in chemistry from the University of North Carolina at Chapel Hill.

About Mayne Pharma
Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange. The company develops and manufactures branded and generic product globally either directly or through distribution partners while applying its drug-delivery expertise for contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world.

Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.

In the United States, Mayne Pharma’s operations consist of two main business segments: The first Metrics Contract Services focuses on contract pharmaceutical services; the other develops and manufactures branded and generic pharmaceutical products.

Through Metrics Contract Services, the company offers pharmaceutical development and manufacturing services to clients worldwide. Areas of expertise include pharmaceutical formulation development; first-time-in-man formulations; clinical trial materials manufacturing for Phase I, II, and III trials; and analytical method development and validation services leading to commercial-scale manufacturing. Capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which Mayne Pharma offers a vast portfolio of drug delivery methods.

To learn more about Metrics Contract Services and Mayne Pharma, visit us online.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sinclair & Co.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Mayne Pharma Names Q. Dwight Lewis VP of Quality for U.S. Operations

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Karen Stinneford - Sinclair-Co.com 
919-833-9102 kys[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sinclair & Co. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

PharmaEssentia Selects Veeva Data Cloud to Support Launch of Novel Therapy for Rare, Chronic Blood Cancers
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050 - A Novel Individualized Neoantigen Cancer Vaccine
DSM Plans New Production Site for Bovaer® in Dalry, Scotland
Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit SkyRFID, LLC





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)